CN112971126A - Total nutrient formula food containing GABA for relieving epilepsy and preparation method thereof - Google Patents
Total nutrient formula food containing GABA for relieving epilepsy and preparation method thereof Download PDFInfo
- Publication number
- CN112971126A CN112971126A CN202110304727.9A CN202110304727A CN112971126A CN 112971126 A CN112971126 A CN 112971126A CN 202110304727 A CN202110304727 A CN 202110304727A CN 112971126 A CN112971126 A CN 112971126A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- formula food
- protein
- premix
- gaba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 235000013305 food Nutrition 0.000 title claims abstract description 44
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 32
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 206010015037 epilepsy Diseases 0.000 title abstract description 33
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000019742 Vitamins premix Nutrition 0.000 claims abstract description 26
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 26
- 235000010755 mineral Nutrition 0.000 claims abstract description 26
- 239000011707 mineral Substances 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 12
- 238000010008 shearing Methods 0.000 claims abstract description 12
- 230000001954 sterilising effect Effects 0.000 claims abstract description 12
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000008132 rose water Substances 0.000 claims abstract description 11
- 235000004789 Rosa xanthina Nutrition 0.000 claims abstract description 8
- 241000109329 Rosa xanthina Species 0.000 claims abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 7
- 239000004519 grease Substances 0.000 claims abstract description 6
- 241000220317 Rosa Species 0.000 claims description 31
- 239000005913 Maltodextrin Substances 0.000 claims description 23
- 229920002774 Maltodextrin Polymers 0.000 claims description 23
- 229940035034 maltodextrin Drugs 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 16
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 12
- 235000019198 oils Nutrition 0.000 claims description 12
- 229930003935 flavonoid Natural products 0.000 claims description 11
- 235000017173 flavonoids Nutrition 0.000 claims description 11
- 150000002215 flavonoids Chemical class 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 235000016709 nutrition Nutrition 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 108010046377 Whey Proteins Proteins 0.000 claims description 9
- 102000007544 Whey Proteins Human genes 0.000 claims description 9
- 229940083466 soybean lecithin Drugs 0.000 claims description 9
- 235000021119 whey protein Nutrition 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 6
- 235000013824 polyphenols Nutrition 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 claims description 5
- 102000011632 Caseins Human genes 0.000 claims description 5
- 108010076119 Caseins Proteins 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003270 Vitamin B Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 210000003022 colostrum Anatomy 0.000 claims description 5
- 235000021277 colostrum Nutrition 0.000 claims description 5
- 238000013329 compounding Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- XBDUTCVQJHJTQZ-UHFFFAOYSA-L iron(2+) sulfate monohydrate Chemical compound O.[Fe+2].[O-]S([O-])(=O)=O XBDUTCVQJHJTQZ-UHFFFAOYSA-L 0.000 claims description 5
- 235000021388 linseed oil Nutrition 0.000 claims description 5
- 239000000944 linseed oil Substances 0.000 claims description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 5
- 239000011564 manganese citrate Substances 0.000 claims description 5
- 235000014872 manganese citrate Nutrition 0.000 claims description 5
- 229940097206 manganese citrate Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 5
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 5
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 229940080237 sodium caseinate Drugs 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000019157 thiamine Nutrition 0.000 claims description 5
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- 239000011721 thiamine Substances 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000019156 vitamin B Nutrition 0.000 claims description 5
- 239000011720 vitamin B Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 229940046010 vitamin k Drugs 0.000 claims description 5
- 229940118149 zinc sulfate monohydrate Drugs 0.000 claims description 5
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims description 4
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 229940071440 soy protein isolate Drugs 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 abstract description 12
- 206010010904 Convulsion Diseases 0.000 abstract description 8
- 239000008347 soybean phospholipid Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 25
- 230000000694 effects Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 8
- 230000001037 epileptic effect Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 244000269722 Thea sinensis Species 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000028329 epileptic seizure Diseases 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000035037 5-HT3 receptors Human genes 0.000 description 2
- 108091005477 5-HT3 receptors Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 2
- 244000215777 Plumeria rubra Species 0.000 description 2
- 235000013087 Plumeria rubra Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 101150017120 sod gene Proteins 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 235000000659 Rosa rugosa Nutrition 0.000 description 1
- 240000006066 Rosa rugosa Species 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000698291 Rugosa Species 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pediatric Medicine (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a total nutrient formula food containing GABA for relieving epilepsy and a preparation method thereof, wherein each 100mL of the total nutrient formula food contains: 3-12 g of protein, 5-20 g of grease, 2-8 g of carbohydrate, 5-20 g of rose water extract, 0.1-0.5 g of GABA, 0.01-0.5 g of tryptophan, 0.05-0.5 g of vitamin premix, 1-10 g of mineral premix, 1-10 g of soybean phospholipid and the balance of water; dissolving the nutrients and the soybean phospholipids in water and grease respectively to obtain a water phase and an oil phase, mixing the water phase and the oil phase together, and performing shearing, homogenizing and sterilization to obtain the full-nutrition formula food. The invention utilizes the antioxidation of roses and the action of tryptophan for relieving oxidative stress and the action of GABA for relieving epilepsy by the synergistic action of various components, and prolongs the seizure period of epilepsy.
Description
The invention relates to a nutritional preparation, in particular to a full nutritional formula food containing GABA for relieving epilepsy and a preparation method thereof, belonging to the technical field of biology.
Background
Epilepsy is a chronic nervous system disease, at present, the epileptic seizure of most patients can be controlled by medication, but some patients have poor response to the anti-epileptic medication, and the epileptic seizure is difficult to control, so that intractable epilepsy is formed. At present, more than 600 million epileptics in China are present, 65-70 million new epileptics are present each year, and about 25 percent of patients are intractable epileptics. Although the current diagnosis and treatment of epilepsy has advanced greatly, the number of intractable epilepsy patients is increasing.
The onset of epilepsy is caused by an imbalance between central nervous system excitation and inhibition, which is mainly associated with changes in ion channels, neurotransmitters and glial cells. The gene mutation can cause the ion channel dysfunction, namely the defective gene codes defective ion channel protein to cause diseases, wherein the research on the correlation of sodium ion, potassium ion and calcium ion channels and epilepsy is more clear; when excitatory neurotransmitter is too much or inhibitory neurotransmitter is too little, imbalance between excitation and inhibition can be caused, neurons are over-discharged, and epilepsy is caused; seizures can result when the astrocytes have altered uptake of glutamate or gamma aminobutyric acid. Among the inhibitory neurotransmitters important in the central nervous system are gamma-aminobutyric acid (GABA) and glycine, and the excitatory neurotransmitters include glutamic acid (Glu) and aspartic acid.
The first suggestion that epileptogenesis is related to intracerebral GABA was that Tower (Mckhann G M, Tower D B. gamma-amino acids: a substrate for oxidative metabolism of cerebral core [ J ]. The American journel of physiology, 1959, 196(1): 36-38.) shows that The GABA content in brain tissue of experimental convulsive animals-cats is significantly reduced.
In 2009, Fretias et al (Fretias R M D, Nasciento K G D, Ferreira P, et al, Neurochemical change on oxidative stress in a thioppocampus duringphase of pirocarpine-induced epilepsy [ J ]. Pharmacology Biochemistry and Behavior 2010, 94: 341-345.) demonstrated by rat experiments that oxidative stress plays an important role in the onset of epilepsy and that the duration of epilepsy was positively correlated with oxidative damage.
Roses (Rosa rugosa Thunb.) are perennial deciduous shrubs, belong to Rosa (Rosaceae) plants, are mainly produced in France, Russia, Baugalia and other countries, and the main planting areas in China are Shandong, Gansu, Yunnan and other places. In China, roses are also a medicinal and edible plant with a long history. In 2010, the ministry of health in China has approved the Rose with double petals (Rose rugosa cv. plina) as a common food resource for food preparation and processing. According to the record of Chinese pharmacopoeia, the rose bud is warm in nature and sweet in taste, and has the effects of promoting blood circulation, regulating menstruation, tranquilizing and allaying excitement, strengthening spleen, treating traumatic injury and the like.
The extraction method of flos Rosae Rugosae is mainly divided into water extraction method and organic solvent extraction method. Zhanglianli et al (Zhanglianli, Daiweifeng, Shujunha, etc.. analysis of flavonoid components in three rose tea and research on antioxidant activity thereof [ J ]. academic newspaper of Kunming science university (Nature science edition), 2019, 44(05): 84-90.) the content of flavonoid components in three rose tea soups is respectively higher than that in methanol extract thereof; the antioxidant activity of the golden edge and the rose tea soup with flat yin are both higher than that of the methanol extract of the golden edge and the rose tea soup with bitter water, and the antioxidant activity of the rose tea soup with bitter water is lower than that of the methanol extract of the rose tea soup with bitter water. The rose extract obtained by organic solvent extraction method is not suitable for food.
The flos Rosae Rugosae contains essential oil, polyphenols, flavonoids, polysaccharides, etc., and has effects of reducing and eliminating free radicals, resisting oxidation, and resisting bacteria.
Alfreda et al (Alfreda wei, Takayuki Shibamoto. Antioxidant Activities and volabile Consistents of valve Essential Oils [ J ]. J Agric Food Chem, 2007, 55(5): 1737-.
The research on the content of total flavonoids in roses and rose attacking residues [ J ] by ultraviolet spectrophotometry of Setron, Zhang Yina, Limin and the like [ J ] agricultural product processing, 2007(4): 19-20.) and Zhouda and the like [ J ] of rose flavonoids in diabetic mice [ J ] food industry science and technology, 2011, 32(2): 319 and 321 ] finds that the flavonoids in roses have the effects of oxidation resistance and blood sugar reduction.
The study on the extraction and efficacy of the frangipani (frangipani. rose polysaccharide [ D ]. joinan: Shandong light industry academy 2010.) finds that the polysaccharide in the rose has the effects of resisting oxidation and tumors.
Researches on plum jade product 36188.
Tryptophan can relieve oxidative stress (NAYAK B N, BUTTAR H S. Evaluation of the antioxidant properties of tryptophans and its metabolites in the vitamin assay [ J ]. Journal of Complementary and integral Medicine, 2016, 13: 129-136.), the oxidative stress can enhance the catabolism of tryptophan, the amino group of tryptophan can be directly combined with an oxidizing agent, the oxidation reaction of other substances can be effectively prevented, and the antioxidant effect can be achieved. Melatonin, a metabolite of tryptophan, acts as a non-enzymatic antioxidant to scavenge free radicals in the body and also has antioxidant activity.
Tryptophan produces 5-hydroxytryptamine in vivo by the catalytic action of tryptophan hydroxylase and aromatic acid decarboxylase, 5-hydroxytryptamine being the most widely affected in epilepsy (Xu W, Orr-Urrerger A, Nigro F, et al, multiorganic Autonochemical function in the peptide linkage the beta2 and the beta4 cosmetics of neuronal nicotinic acid receptors [ J ]. J Neurosci, 1999, 19(21): 9298. cnotr 9305.), 5-hydroxytryptamine binds to 5-HT3 receptor, causes neuronal depolarization by changing the permeability of Na +, K + and Ca2+, can inhibit epileptic seizures (Zhao H, Lin Y, Chen S, et al. 5-HT3 receptors: a potential therapeutic target for epilepsy [ 2018, Current). The rose and the tryptophan have the effects of eliminating free radicals and resisting oxidation, and can relieve oxidative stress, so that the epilepsy is relieved; meanwhile, tryptophan can be metabolized in vivo to generate 5-hydroxytryptamine, so that epileptic seizure is inhibited, and based on the principle, a full-nutrition formula food containing GABA and used for relieving epilepsia and a preparation method thereof are prepared.
Disclosure of Invention
The invention provides a full-nutrition formula food containing GABA and used for relieving epilepsy and a preparation method thereof, and aims to prolong the seizure period of a patient by utilizing the influence of the metabolism of roses and amino acid in a body on oxidative stress. The invention provides a total nutrient formula food containing GABA for relieving epilepsy, which is an emulsion and is prepared by the following steps:
firstly, the compounding of full-nutrition formula food
The total nutritional formula contains per 100 mL:
3-12 g of protein, wherein the protein is a protein,
5-20 g of grease,
2-8 g of carbohydrate,
5-20 g of rose water extract,
GABA 0.1~0.5 g,
0.01 to 0.5 g of tryptophan,
0.05-0.5 g of vitamin premix,
1-10 g of mineral premix,
1-10 g of soybean lecithin,
the balance being water.
The protein is one or a mixture of more of concentrated whey protein, hydrolyzed whey protein, soy protein isolate and sodium caseinate.
The oil is one or more of soybean oil, peanut oil, linseed oil, perilla seed oil and medium chain triglyceride.
The carbohydrate is one or a mixture of more of maltodextrin and fructo-oligosaccharide.
The rose water extract is filtrate obtained by soaking rose flowers at 70-90 ℃ for 10-20 min according to a material-liquid ratio of 1: 10-1: 25 (g: mL) and filtering, and is concentrated by using a rotary evaporator, wherein the solid content in the filtrate after concentration is 40-60%, polysaccharide is 0.1-0.5 g/L, flavonoid is 0.5-1.5 g/L, and polyphenol is 150-200 g/L.
The mineral premix comprises, by 1g, 30-80 mg of calcium carbonate, 15-20 mg of magnesium chloride, 50-100 mg of edible salt, 80-150 mg of potassium chloride, 20-60 mg of monopotassium phosphate, 0.5-1.0 mg of ferrous sulfate monohydrate, 0.2-0.6 mg of zinc sulfate monohydrate, 0.001-0.01 mg of sodium selenite, 0.03-0.06 mg of anhydrous copper sulfate, 0.01-0.05 mg of manganese citrate, 0.005-0.01 mg of potassium iodide and the balance of a mineral premix carrier.
The mineral premix carrier is maltodextrin.
The vitamin premix comprises, by 1g, 2-5 mg of vitamin A, 0.03-0.06 mg of vitamin D, 250-500 mg of ascorbic acid, 30-60 mg of vitamin E, 10.1-0.5 mg of vitamin K, 3-6 mg of thiamine, 2-6 mg of riboflavin, 8-15 mg of nicotinamide, 15-20 mg of pantothenic acid, 3-6 mg of pyridoxine hydrochloride, 0.5-2.5 mg of folic acid, 0. 120.003-0.020 mg of vitamin B, 0.05-0.25 mg of biotin and the balance of a vitamin premix carrier.
The vitamin premix carrier is maltodextrin.
Preparation of full-nutrient formula food
Water phase: adding protein, carbohydrate, mineral premix, vitamin premix, GABA, tryptophan and rose extract into distilled water at the temperature of 30-60 ℃, and fully stirring until the protein, carbohydrate, mineral premix, vitamin premix, GABA, tryptophan and rose extract are dissolved;
oil phase: adding the emulsifier into the grease, and fully stirring until the emulsifier is dissolved;
uniformly mixing the water phase and the oil phase, and uniformly mixing by using a high-speed shearing machine, wherein the rotating speed is 1500-3000 r/min, and the shearing time is 5-20 min to obtain primary emulsion;
homogenizing the colostrum by using a high-pressure homogenizer under the following homogenizing conditions: homogenizing for 2-8 times at 200-800 bar;
after homogenizing, filling and sterilizing, wherein the sterilization conditions are as follows: 110-125 ℃ for 10-30 min; taking out and cooling to room temperature to obtain the total nutrient formula food.
The full-nutrition formula food provided by the invention contains proteins such as soybean protein isolate and concentrated whey protein, has rich nitrogen source, better supplements the needed protein, is rich in unsaturated fatty acids such as medium-chain fatty acid and DHA, and has important inhibition effect on oxidative stress of epilepsy.
The total nutrient formula food provided by the invention is particularly added with GABA, tryptophan and rose extract, wherein GABA can increase the content of GABA in brain, maintain the balance between excitatory neurotransmitter and inhibitory neurotransmitter in brain, tryptophan can relieve oxidative stress and metabolize to generate 5-hydroxytryptamine, and the rose extract has the effects of reducing and eliminating free radicals, resisting oxidation and the like, relieves oxidative stress and achieves the effect of relieving epilepsy.
The total nutrient formula food provided by the invention adopts carbohydrates with low Glycemic Index (GI) such as maltodextrin, and is beneficial to the control of blood sugar of patients.
The total nutrient formula food provided by the invention is a composite food, combines proteins such as soybean protein isolate, concentrated whey protein and the like, supplements required proteins, combines rose and tryptophan to relieve the oxidative stress of epileptics, combines maltodextrin and other carbohydrates with low GI (glucose) to control the blood sugar of patients, relieves the oxidative stress of epileptics through the synergistic effect of various components, improves the immunity of patients, and relieves the attack of epileptics. The GABA-containing full-nutrition formula food for relieving epilepsy can be used as a nutritional food for providing nutritional support for intractable epilepsy patients, and can also be used as nutritional support for common epilepsy patients.
Example 1:
firstly, the compounding of full-nutrition formula food
The total nutritional formula contains per 100 mL:
6 g of the isolated soy protein is prepared,
10 g of linseed oil, namely 10 g of linseed oil,
4 g of maltodextrin, namely 4 g of maltodextrin,
10 g of rose water extract liquid,
GABA 0.25 g,
0.19 g of tryptophan (tryptophan) is added,
0.2 g of vitamin premix,
5 g of mineral premix, namely 5 g of mineral premix,
4 g of soybean lecithin, namely 4 g of soybean lecithin,
the balance being water.
The rose water extract is filtrate obtained by soaking rose according to the material-liquid ratio of 1:20 (g: mL) at 80 ℃ for 15 min and then filtering, and is concentrated by using a rotary evaporator, wherein the solid content in the filtrate after concentration is 50%, polysaccharide is 0.21 g/L, flavonoid is 0.78 g/L, and polyphenol is 180 g/L.
1g of mineral premix comprises 56 mg of calcium carbonate, 18.3 mg of magnesium chloride, 83 mg of edible salt, 111 mg of potassium chloride, 40 mg of monopotassium phosphate, 0.83 mg of ferrous sulfate monohydrate, 0.4 mg of zinc sulfate monohydrate, 0.003 mg of sodium selenite, 0.044 mg of anhydrous copper sulfate, 0.025 mg of manganese citrate, 0.007 mg of potassium iodide and the balance of maltodextrin.
The vitamin premix 1g comprises 3.6 mg of vitamin A, 0.048 mg of vitamin D, 336 mg of ascorbic acid, 48 mg of vitamin E, 10.264 mg of vitamin K, 4.2 mg of thiamine, 4.2 mg of riboflavin, 12 mg of nicotinamide, 17.4 mg of pantothenic acid, 4.2 mg of pyridoxine hydrochloride, 1.332 mg of folic acid, 120.0078 mg of vitamin B, 0.132 mg of biotin and the balance of maltodextrin. The vitamin premix carrier is maltodextrin.
Preparation of full-nutrient formula food
Water phase: adding soybean protein isolate, maltodextrin, mineral premix, vitamin premix, GABA, tryptophan and rose extract into distilled water of 40 ℃, and fully stirring until the soybean protein isolate, the maltodextrin, the mineral premix, the vitamin premix, the GABA, the tryptophan and the rose extract are dissolved;
oil phase: adding soybean lecithin into linseed oil, and fully stirring until the soybean lecithin is dissolved;
uniformly mixing the water phase and the oil phase, and uniformly mixing by using a high-speed shearing machine, wherein the rotating speed is 2500 r/min, and the shearing time is 15 min to obtain primary emulsion;
homogenizing the colostrum by using a high-pressure homogenizer under the following homogenizing conditions: 600 bar, homogenizing for 4 times;
after homogenizing, filling and sterilizing, wherein the sterilization conditions are as follows: at 115 ℃ for 20 min; taking out and cooling to room temperature to obtain the total nutrient formula food.
Example 2:
firstly, the compounding of full-nutrition formula food
The total nutritional formula contains per 100 mL:
3 g of concentrated whey protein is added into the concentrated whey protein,
5 g of purple perilla seed oil,
2 g of fructo-oligosaccharide,
the rose water extract is 5 g,
GABA 0.1 g,
0.1 g of tryptophan is added in the feed,
0.1 g of vitamin premix,
2 g of mineral premix, namely 2 g of mineral premix,
2 g of soybean lecithin,
the balance being water.
The rose water extract is filtrate obtained by soaking rose according to the material-liquid ratio of 1:10 (g: mL) at 70 ℃ for 20 min and then filtering, and is concentrated by using a rotary evaporator, wherein the solid content in the filtrate after concentration is 60%, polysaccharide is 0.1 g/L, flavonoid is 0.5 g/L, and polyphenol is 150 g/L.
1g of mineral premix comprises 56 mg of calcium carbonate, 18.3 mg of magnesium chloride, 83 mg of edible salt, 111 mg of potassium chloride, 40 mg of monopotassium phosphate, 0.83 mg of ferrous sulfate monohydrate, 0.4 mg of zinc sulfate monohydrate, 0.003 mg of sodium selenite, 0.044 mg of anhydrous copper sulfate, 0.025 mg of manganese citrate, 0.007 mg of potassium iodide and the balance of maltodextrin.
The vitamin premix 1g comprises 3.6 mg of vitamin A, 0.048 mg of vitamin D, 336 mg of ascorbic acid, 48 mg of vitamin E, 10.264 mg of vitamin K, 4.2 mg of thiamine, 4.2 mg of riboflavin, 12 mg of nicotinamide, 17.4 mg of pantothenic acid, 4.2 mg of pyridoxine hydrochloride, 1.332 mg of folic acid, 120.0078 mg of vitamin B, 0.132 mg of biotin and the balance of maltodextrin. The vitamin premix carrier is maltodextrin.
Preparation of full-nutrient formula food
Water phase: adding concentrated whey protein, fructo-oligosaccharide, mineral premix, vitamin premix, GABA, tryptophan and rose extract into distilled water of 30 deg.C, and stirring thoroughly to dissolve;
oil phase: adding soybean phospholipid into perilla seed oil, and stirring to dissolve;
uniformly mixing the water phase and the oil phase, and uniformly mixing by using a high-speed shearing machine, wherein the rotating speed is 1500 r/min, and the shearing time is 20 min to obtain primary emulsion;
homogenizing the colostrum by using a high-pressure homogenizer under the following homogenizing conditions: homogenizing at 200 bar for 8 times;
after homogenizing, filling and sterilizing, wherein the sterilization conditions are as follows: 110 ℃ for 30 min; taking out and cooling to room temperature to obtain the total nutrient formula food.
Example 3:
firstly, the compounding of full-nutrition formula food
The total nutritional formula contains per 100 mL:
12 g of sodium caseinate, namely 12 g,
20 g of medium-chain triglycerides, 20 g,
8 g of maltodextrin, namely 8 g of maltodextrin,
20 g of rose water extract liquid,
GABA 0.5 g,
0.25 g of tryptophan was added thereto,
0.5 g of vitamin premix,
10 g of mineral premix, namely 10 g of mineral premix,
8 g of soybean lecithin (soybean lecithin),
the balance being water.
The rose water extract is filtrate obtained by soaking rose according to the material-liquid ratio of 1:30 (g: mL) at 90 ℃ for 10 min and then filtering, and is concentrated by using a rotary evaporator, wherein the solid content in the filtrate after concentration is 40%, polysaccharide is 0.5 g/L, flavonoid is 1.5 g/L, and polyphenol is 200 g/L.
1g of mineral premix comprises 56 mg of calcium carbonate, 18.3 mg of magnesium chloride, 83 mg of edible salt, 111 mg of potassium chloride, 40 mg of monopotassium phosphate, 0.83 mg of ferrous sulfate monohydrate, 0.4 mg of zinc sulfate monohydrate, 0.003 mg of sodium selenite, 0.044 mg of anhydrous copper sulfate, 0.025 mg of manganese citrate, 0.007 mg of potassium iodide and the balance of maltodextrin.
The vitamin premix 1g comprises 3.6 mg of vitamin A, 0.048 mg of vitamin D, 336 mg of ascorbic acid, 48 mg of vitamin E, 10.264 mg of vitamin K, 4.2 mg of thiamine, 4.2 mg of riboflavin, 12 mg of nicotinamide, 17.4 mg of pantothenic acid, 4.2 mg of pyridoxine hydrochloride, 1.332 mg of folic acid, 120.0078 mg of vitamin B, 0.132 mg of biotin and the balance of maltodextrin. The vitamin premix carrier is maltodextrin.
Preparation of full-nutrient formula food
Water phase: adding sodium caseinate, maltodextrin, mineral premix, vitamin premix, GABA, tryptophan and rose extract into distilled water at 50 ℃, and fully stirring until the sodium caseinate, the maltodextrin, the mineral premix, the vitamin premix, the GABA, the tryptophan and the rose extract are dissolved;
oil phase: adding soybean phospholipid into medium chain triglyceride, and stirring to dissolve;
uniformly mixing the water phase and the oil phase, and uniformly mixing by using a high-speed shearing machine at the rotating speed of 3000 r/min for 10 min to obtain primary emulsion;
homogenizing the colostrum by using a high-pressure homogenizer under the following homogenizing conditions: 800 bar, homogenizing for 2 times;
after homogenizing, filling and sterilizing, wherein the sterilization conditions are as follows: at 121 ℃ for 10 min; taking out and cooling to room temperature to obtain the total nutrient formula food.
The full-nutrition formula food provided by the invention has the following effects on the epileptic attack of mice:
constructing an epilepsia mouse model, taking the test of the example 1-3, only irrigating the stomach, setting a negative control group at the same time, irrigating the stomach with physiological saline of the negative control group, and normally feeding. Kunming mice, male, weight 18-22 g, each group of 10. Mice were gavaged daily for 7 consecutive days at a dose of 0.05 g/10 g. Weighing 1 time every day, observing the disease condition, taking blood from eyeball after last gastric lavage for 1 h, and detecting malondialdehyde content and enzyme activities of superoxide dismutase, glutathione peroxidase and SOD with malondialdehyde detection kit (Nanjing institute of bioengineering), superoxide dismutase detection kit (Nanjing institute of bioengineering), glutathione peroxidase detection kit (Nanjing institute of bioengineering), and SOD commercial detection kit (Biyuntian). The results of the influence of the formula food for special medical application of epileptics on the body weight of a mouse are shown in table 1, the results of the influence on the attack of epilepsy are shown in table 2, and the influences on the malonaldehyde content and the enzyme activity are shown in table 3.
TABLE 1 Effect of the Total nutrient formula on mouse body weight
Initial body weight (g) gain (g)
Example 123.6729.075.40
Example 223.7028.204.50
Example 323.6628.725.06
Negative control group 23.6428.474.83
As can be seen from Table 1, there was no significant difference in the weight gain (P > 0.05) in the mice of examples 1-3, compared to the negative control group. Therefore, the preparation has no obvious influence on the weight increase of mice, and can maintain the normal physiological function of the mice.
TABLE 2 Effect of the Total nutrient formula on the onset of epilepsy in mice
Prolonged attack time compared to negative control group
Example 140 s
Example 230 s
Example 335 s
As can be seen from Table 2, the total nutrient formula food provided by the invention can obviously prolong the seizure cycle of mice and is beneficial to relieving epilepsy.
TABLE 3 Effect of the Total nutrient formula on the blood indices of mice
GSH-Px(μmol/L) CAT(U/g) SOD(U/mL) MDA(nmol/mL)
Example 132.46. + -. 2.6893.71. + -. 10.4819.34. + -. 2.4340.63. + -. 7.25
Example 225.55. + -. 2.2490.08. + -. 20.9118.62. + -. 2.7744.41. + -. 6.53
Example 321.51. + -. 2.6787.42. + -. 21.4718.14. + -. 1.7955.35. + -. 6.40
Negative control group 18.89 + -2.9585.00 + -14.1415.23 + -2.0160.05 + -7.02
As can be seen from Table 3, the total nutrient formula food provided by the invention can improve the enzyme activities of superoxide dismutase, glutathione peroxidase and SOD and reduce the content of malondialdehyde relative to a negative control group, and can relieve the epilepsy of mice.
Claims (8)
1. Firstly, the compounding of full-nutrition formula food
The total nutritional formula contains per 100 mL:
3-12 g of protein, wherein the protein is a protein,
5-20 g of grease,
2-8 g of carbohydrate,
5-20 g of rose water extract,
GABA 0.1~0.5 g,
0.01 to 0.5 g of tryptophan,
0.05-0.5 g of vitamin premix,
1-10 g of mineral premix,
1-10 g of soybean lecithin,
the balance of water;
preparation of full-nutrient formula food
Water phase: adding protein, carbohydrate, mineral premix, vitamin premix, GABA, tryptophan and rose extract into distilled water at the temperature of 30-50 ℃, and fully stirring until the protein, carbohydrate, mineral premix, vitamin premix, GABA, tryptophan and rose extract are dissolved;
oil phase: adding the emulsifier into the grease, and fully stirring until the emulsifier is dissolved;
uniformly mixing the water phase and the oil phase, and uniformly mixing by using a high-speed shearing machine, wherein the rotating speed is 1500-3000 r/min, and the shearing time is 10-20 min to obtain primary emulsion;
homogenizing the colostrum by using a high-pressure homogenizer under the following homogenizing conditions: homogenizing for 2-8 times at 200-800 bar;
after homogenizing, filling and sterilizing, wherein the sterilization conditions are as follows: 110-125 ℃ for 10-30 min; taking out and cooling to room temperature to obtain the total nutrient formula food.
2. The nutritionally complete formula according to claim 1, wherein the protein is one or a mixture of several of concentrated whey protein, hydrolysed whey protein, soy protein isolate and sodium caseinate.
3. The nutritionally complete formula according to claim 1, wherein said oil or fat is one or a mixture of several of soybean oil, peanut oil, linseed oil, perilla seed oil and medium chain triglycerides.
4. The nutritionally complete formula according to claim 1, wherein the carbohydrate is one or a mixture of two of maltodextrin and fructooligosaccharides.
5. The total nutrient formula food as claimed in claim 1, wherein the rose water extract is a filtrate obtained by soaking roses at 70-90 ℃ for 10-20 min according to a material-liquid ratio of 1: 10-1: 25 (g: mL) and filtering, and is concentrated by a rotary evaporator, wherein the solid content in the concentrated filtrate is 40-60%, the polysaccharide content is 0.1-0.5 g/L, the flavonoid content is 0.5-1.5 g/L, and the polyphenol content is 150-200 g/L.
6. The full-nutrition formula food as claimed in claim 1, wherein 1g of the mineral premix comprises 30-80 mg of calcium carbonate, 15-20 mg of magnesium chloride, 50-100 mg of edible salt, 80-150 mg of potassium chloride, 20-60 mg of monopotassium phosphate, 0.5-1.0 mg of ferrous sulfate monohydrate, 0.2-0.6 mg of zinc sulfate monohydrate, 0.001-0.01 mg of sodium selenite, 0.03-0.06 mg of anhydrous copper sulfate, 0.01-0.05 mg of manganese citrate, 0.005-0.01 mg of potassium iodide, and the balance of mineral premix carrier.
7. The total nutrient formula food as claimed in claim 1, wherein 1g of the vitamin premix comprises 2-5 mg of vitamin A, 0.03-0.06 mg of vitamin D, 250-500 mg of ascorbic acid, 30-60 mg of vitamin E, 10.1-0.5 mg of vitamin K, 3-6 mg of thiamine, 2-6 mg of riboflavin, 8-15 mg of nicotinamide, 15-20 mg of pantothenic acid, 3-6 mg of pyridoxine hydrochloride, 0.5-2.5 mg of folic acid, 120.003-0.020 mg of vitamin B, 0.05-0.25 mg of biotin, and the balance of a vitamin premix carrier.
8. The total nutrient formula food according to claim 1, wherein the shearing speed is 1500 to 3000 r/min, and the shearing time is 10 to 20 min; the homogenization conditions were: homogenizing for 2-8 times at 200-800 bar; the sterilization conditions are as follows: 110-125 ℃ for 10-30 min.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110304727.9A CN112971126A (en) | 2021-03-23 | 2021-03-23 | Total nutrient formula food containing GABA for relieving epilepsy and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110304727.9A CN112971126A (en) | 2021-03-23 | 2021-03-23 | Total nutrient formula food containing GABA for relieving epilepsy and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112971126A true CN112971126A (en) | 2021-06-18 |
Family
ID=76332960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110304727.9A Withdrawn CN112971126A (en) | 2021-03-23 | 2021-03-23 | Total nutrient formula food containing GABA for relieving epilepsy and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112971126A (en) |
-
2021
- 2021-03-23 CN CN202110304727.9A patent/CN112971126A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008258958B2 (en) | Anti-fatigue Agents and Oral Compositions Containing Andrographolide as Active Ingredient | |
US20060024385A1 (en) | Metabolic capacity enhancing compositions and methods for use in a mammal | |
TW202103574A (en) | Sports and nutritional supplement formulations | |
MXPA06012501A (en) | Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite. | |
EP3173089B1 (en) | Agent for improving brain function and agent for preventing cognitive impairment | |
KR20010079981A (en) | Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders | |
EP1562447B1 (en) | Antioxidative compositions | |
EP2859896B1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
CA2566612A1 (en) | Uridine effects on dopamine release | |
US10653655B2 (en) | Composition for preventing or improving peripheral neuropathy | |
KR102011033B1 (en) | Composition for enhancing cognitive function comprising tea extraction which has modified amount of ingredients | |
KR20240078638A (en) | Composition for protecting cell from oxidation stress comprising tea extraction which has modified amount of ingredients | |
US20150050260A1 (en) | Pyrroloquinoline quinone based compositions and uses | |
KR20110119305A (en) | A functional beverage comprising taurine, royal jelly, red ginseng, lycii fructus, glumate and apple essence as main ingredients | |
WO2014047614A1 (en) | Nutritional compositions and methods for enhancing cognitive function and muscle function | |
AT513274A4 (en) | Dietary supplements | |
US10799551B2 (en) | Composition for enhancing cognitive function comprising green tea extract which has modified amounts of ingredients | |
CN111493315A (en) | Memory-improving antioxidant composition and application thereof | |
CN112971126A (en) | Total nutrient formula food containing GABA for relieving epilepsy and preparation method thereof | |
KR101401612B1 (en) | Composition comprising extract of punica granatum for prevention and treatment of stress diseases | |
CN112544965A (en) | Rose based medical formula food for relieving epilepsy and preparation method thereof | |
JP2005082495A (en) | Cerebral cell-protecting composition | |
WO2003039570A1 (en) | Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory | |
KR102054194B1 (en) | Anti-obesity composition comprising Suaeda japonica extract as effective component | |
JP2003286164A (en) | Acetylcholine esterase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210618 |